Nirmatrelvir/ritonavir(NMV/r) and Molnupiravir(MOL), oral antivirals for COVID-19, are highly effective treatment for symptom relief and reducing mortality risk in patients with mild to moderate COVID-19. However, real-world safety data are still limited. This study aimed to evaluate the association between NMV/r, MOL and adverse events(AEs), and identify safety signals not previously known. To identify major adverse events and safety signals associated with NMV/r and MOL, we conducted pharmacovigilance study using drug-related AEs reported to KIDS KAERS DB(2305A0011). Disproportionality analysis were performed using reporting odds ratio (ROR) and information component (IC) method to detected new safety signals not listed in drug label. In this study, AEs reported following the use of NMV/r and MOL were generally not serious and resembled results of previous studies. However, with NMV/r, new safety signals such as olfactory nerve disorders, urinary AEs, appetite disorders, and hallucinations were detected. Also, some cardiovascular AEs were identified after MOL usage, which were not listed on drug label. We expected this study to provide basic data of safety for oral antivirals of COVID-19 available in Korea and may contribute to the development of future drug safety guidelines.